This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information

Homepage
Let's collaborate Boehringer Ingelheim
Welcome to
InOncology.com

A knowledge hub developed to provide information and education in oncology for healthcare professionals.

VISIT OUR ONCOLOGY YOUTUBE CHANNEL
Rate this
We are giving patients new hope

Our highlights

GioTag study animation
Find out more

Watch this animation about sequential therapy with afatinib* followed by osimertinib

GI cancers in focus
Find out more

Browse this introductory overview of gastrointestinal cancers

SOS1-KRAS-interaction-inhibitor
Find out more

Find out about our first-in-class investigational SOS1::KRAS interaction inhibitor**

LATEST CONGRESSES: OUR ACTIVITIES

Past event
ASCO 2019
ASCO 2019
Access materials presented at ASCO; 5 publications and 5 downloads
Past event
WCLC 2019
WCLC 2019
Access materials presented at WCLC; 8 publications and 8 downloads
Past event
ESMO 2019
ESMO 2019
Access materials presented at ESMO; 6 publications and 10 downloads

Physicians´ insights

Sequencing to prolong the chemotherapy-free period
Professor Barbara Melosky
Sequencing to prolong the chemotherapy-free period
Vanesa Gregorc
Professor Vanesa Gregorc
Sequencing algorithms in NSCLC
Professor Nir Pelend discusses treatment strategies in EGFRm+ NSCLC
Professor Nir Peled
Treatment strategies in EGFRm+ NSCLC
Common options for uncommon mutations
Professor James Yang
Common options for uncommon mutations
Prof Schuler discusses improving outcomes for patients with brain metastases
Professor Martin Schuler
Improving outcomes for patients with brain metastases
Squamous NSCLC: where do EGFR TKIs fit in?
Dr Noemi Reguart
Squamous NSCLC: where do EGFR TKIs fit in?
Maximilian Hochmair
Dr Maximillian Hochmair
Non-mutated, adenocarcinoma NSCLC: options after immunotherapy plus chemotherapy
Prof Reck discusses recent changes and sequencing strategies in non mutated, non-squamous advanced NSCLC
Professor Martin Reck
Recent changes and sequencing strategies in non-mutated, non-squamous advanced NSCLC

RESOURCES

Lung and GI cancers in focus
Slide Bank

Explore our introductory overview of gastrointestinal cancers

Colorectal cancer slide decks
SLIDE BANK

Browse our slide decks on colorectal cancer

Uncommon- EGFR mutations- hexagon chain
Find out more

Data on use of afatinib in patients with NSCLC and uncommon EGFR mutations

Data on nintedanib after immune checkpoint inhibitors
EXPLORE

Nintedanib^ after immunotherapy: emerging data from the VARGADO study

Therapeutic strategies
Coming soon

Slide bank – therapeutic strategies: cancer cell-directed and immuno-oncology approach

*Afatinib is approved in more than 80 markets, including the EU, Japan, Taiwan and Canada under the brand name GIOTRIF®, in the US under the brand name GILOTRIF® and in India under the brand name Xovoltib®; for the full list, please click here. Registration conditions differ internationally; please refer to locally approved prescribing information.

**This is an investigational compound and has not been approved. Its safety and efficacy have not been established.

^Nintedanib is approved in the EU under the brand name VARGATEF® for use in combination with docetaxel in adult patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma tumour histology after first-line chemotherapy. For the full list of country-specific information, please click here. Nintedanib is not approved in other oncology indications.

 

© 2019 Boehringer Ingelheim International GmbH. All rights reserved.

Page last updated: October 2019

Back to top